Latest filings (excl ownership)
10-Q
2024 Q1
Quarterly report
9 May 24
8-K
MariMed Reports First Quarter 2024 Earnings
8 May 24
ARS
2024 FY
Annual report to shareholders
29 Apr 24
DEF 14A
Definitive proxy
29 Apr 24
10-K
2023 FY
Annual report
7 Mar 24
8-K
MariMed Reports Fourth Quarter and Full Year 2023 Earnings
6 Mar 24
8-K
Entry into a Material Definitive Agreement
20 Nov 23
10-Q
2023 Q3
Quarterly report
9 Nov 23
8-K
MariMed Reports Third Quarter 2023 Earnings
8 Nov 23
8-K
Departure of Directors or Certain Officers
3 Nov 23
10-Q
2023 Q2
Quarterly report
4 Aug 23
8-K
MariMed Reports Second Quarter 2023 Earnings
2 Aug 23
8-K
Submission of Matters to a Vote of Security Holders
12 Jun 23
10-Q
2023 Q1
Quarterly report
9 May 23
8-K
MariMed Reports First Quarter 2023 Earnings
8 May 23
ARS
2023 FY
Annual report to shareholders
27 Apr 23
DEF 14A
Definitive proxy
27 Apr 23
8-K
MariMed Expands Board With the Addition of Kathleen Tucker
17 Apr 23
S-8
Registration of securities for employees
7 Mar 23
8-K
Amendments to Articles of Incorporation or Bylaws
6 Mar 23
10-K
2022 FY
Annual report
3 Mar 23
8-K
MariMed Reports Fourth Quarter
1 Mar 23
8-K
MariMed Closes $35 Million Credit Facility
24 Jan 23
8-K
MariMed Appoints Jon Levine as Interim Chief Executive Officer
14 Dec 22
8-K
Other Events
12 Dec 22
10-Q
2022 Q3
Quarterly report
8 Nov 22
8-K
MariMed Reports Third Quarter 2022 Earnings
7 Nov 22
8-K
Submission of Matters to a Vote of Security Holders
31 Oct 22
DEF 14A
Definitive proxy
22 Sep 22
8-K
Departure of Directors or Certain Officers
7 Sep 22
10-Q
2022 Q2
Quarterly report
9 Aug 22
8-K
MariMed Reports Second Quarter 2022 Earnings
8 Aug 22
8-K
Departure of Directors or Certain Officers
18 May 22
8-K
MariMed Reports First Quarter 2022 Earnings
16 May 22
10-Q
2022 Q1
Quarterly report
10 May 22
8-K
MariMed Receives Maryland State Approval for Transfer of Ownership of Kind Therapeutics USA
14 Apr 22
8-K
Results of Operations and Financial Condition
21 Mar 22
10-K
2021 FY
Annual report
16 Mar 22
8-K
MariMed Announces Agreement to Acquire Kind Therapeutics USA, LLC, A Maryland Licensed Vertically Integrated Cannabis Business
5 Jan 22
Latest ownership filings
4
Timothy Shaw
29 Apr 24
4
Jon R Levine
29 Apr 24
4
Timothy Shaw
3 Apr 24
4
Jon R Levine
3 Apr 24
4
Timothy Shaw
11 Mar 24
4
Jon R Levine
11 Mar 24
4
Jon R Levine
9 Nov 23
4
Jon R Levine
30 Oct 23
4
Timothy Shaw
30 Oct 23
4
Timothy Shaw
6 Sep 23
4
Eva M.D. Selhub
8 Jun 23
4
Kathleen Tucker
8 Jun 23
4
David R Allen
8 Jun 23
4
Edward J Gildea
8 Jun 23
4
Timothy Shaw
1 May 23
4
Jon R Levine
1 May 23
4
Edward J Gildea
1 May 23
4
Eva M.D. Selhub
1 May 23
4
David R Allen
1 May 23
3
Kathleen Tucker
19 Apr 23
4
Timothy Shaw
14 Mar 23
4
Jon R Levine
14 Mar 23
4
Susan M. Villare
14 Mar 23
4
David R Allen
31 Oct 22
4
Eva M.D. Selhub
31 Oct 22
4
Robert N Fireman
31 Oct 22
4
Jon R Levine
31 Oct 22
4
Timothy Shaw
31 Oct 22
4
Edward J Gildea
31 Oct 22
3/A
Timothy Shaw
29 Sep 22
3
Susan M. Villare
18 May 22
4
Jon R Levine
14 Jan 22
4
Robert N Fireman
14 Jan 22
4
Timothy Shaw
5 Oct 21
4
Jon R Levine
5 Oct 21
4
Robert N Fireman
5 Oct 21
3
Timothy Shaw
13 Jul 21
4
Robert N Fireman
13 Jul 21
4
David R Allen
13 Jul 21
4
Timothy Shaw
13 Jul 21